Research and Markets: Booming Clinical Trials Market in India

DUBLIN--(BUSINESS WIRE)--Research and Markets

According to our research report, "Booming Clinical Trials Market in India", India promises to be one of the hottest destinations for conducting global clinical research, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings.

India presently occupies a very small pie of the global opportunity. The total number of clinical trials in India stood at 221 in 2007, which equates to less than 2% of the global clinical trials. With all major pharmaceutical/biotech companies and CROs establishing their presence in India, the number of clinical trials in the country is expected to grow several fold in the next five years. The country is projected to conduct nearly 5% of the global clinical trials by 2012. However, to achieve its goal of becoming a global hub of clinical trials, the country has to overcome challenges like unethical trials, delay in trial approval, inappropriate protection of clinical data, and lack of Good Clinical Practice (GCP) certified sites and investigators.

Surging clinical trials market in India will create enormous opportunities for a number of associated industries, including IVD market, education sector and clinical data management.

"Booming Clinical Trials Market in India" gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages/disadvantages India has in becoming a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look at before outsourcing clinical trials to a country. These include parameters such as patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials. Thus, this analytical study serves as a useful guide for drug manufacturers, CROs, consultants and investors who are planning to enter the Indian clinical trials market.